Research summaries for everyoneNot medical advice
Tirzepatide research reference vial, Elevated Pharma

Research reference · Weight & Metabolism

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist and the active ingredient in two FDA-approved medicines, Mounjaro and Zepbound. Its trial record is one of the largest of any peptide in this library.

Published by Elevated Pharma ·

Weight & MetabolismFDA-labeled drug reference

Identity

What is Tirzepatide?

A synthetic, acylated 39-residue peptide (development code LY3298176) that activates GIP and GLP-1 receptors.

Research context

What has Tirzepatide been studied for?

The SURPASS (type 2 diabetes) and SURMOUNT (obesity) phase 3 programs are published, including head-to-head trials against semaglutide, a weight-maintenance trial and a three-year diabetes-prevention analysis.

Evidence boundary

What does the research not show?

Approval and trial results apply to the approved products as labeled. They do not transfer to an unlabeled research material or another supplier’s product.

U.S. status · November 7, 2026

Is Tirzepatide FDA-approved?

FDA-approved as Mounjaro (type 2 diabetes, including children 10 and older since late 2025) and Zepbound (chronic weight management and obstructive sleep apnea). FDA approved a multi-dose Zepbound KwikPen in February 2026.

Research updates

What’s new

Dated developments for Tirzepatide, newest first. See all research updates.

  1. Psoriatic arthritis data at ACR

    Lilly presents TOGETHER-PsA, a phase 3b study of ixekizumab with tirzepatide in psoriatic arthritis with obesity.

    Read the source
  2. Zepbound KwikPen

    FDA approved a four-dose, single-patient Zepbound pen.

    Read the source

Key studies

The main Tirzepatide research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 2,748 PubMed records for Tirzepatide · Counts and selections checked November 7, 2026.

Reference identifiers

Tirzepatide identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
Tirzepatide
Also indexed as
LY3298176
Molecular formula
C225H348N48O68
Molecular mass
4813 g/mol
PubChem CID
166567236

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.